Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 70 peer-reviewed journal articles Updated
Endocrinology · Vasoactive Intestinal Peptide-Producing Tumor (VIPoma)

VIPoma (Vasoactive Intestinal Peptide producing tumor): A Patient Guide

At a Glance

VIPoma is a rare tumor that releases too much VIP, causing WDHA syndrome with watery diarrhea, dangerously low potassium, and dehydration. Prompt fluid and electrolyte replacement is essential, followed by tumor treatment and lifelong monitoring.

VIPoma is an exceptionally rare type of neuroendocrine tumor, estimated to affect only about one in every 10 million people each year [1]. While most commonly found in the pancreas, the tumor is defined by its ability to overproduce a hormone called Vasoactive Intestinal Peptide (VIP) [2]. In a healthy body, VIP helps regulate digestion, but a VIPoma releases it in massive, uncontrolled amounts, triggering a condition known as WDHA syndrome [3]. This syndrome is named for its core symptoms: Watery Diarrhea, Hypokalemia (dangerously low potassium), and Achlorhydria (low stomach acid) [3].

The clinical threat of a VIPoma often stems from this hormonal surge, although the tumor’s grade, burden, and spread remain clinically important [4]. The volume of fluid loss can be staggering—sometimes exceeding three liters per day—leading to profound dehydration, kidney injury, and dangerous electrolyte imbalances [5][6]. Because of this, treatment often requires an acute stabilization phase focused on rehydration and mineral replacement [4]. Medical teams often use medications called somatostatin analogs to rapidly reduce the diarrhea and allow the body to recover its balance [7][8].

Once the immediate crisis is under control, care shifts to managing the tumor. For tumors that have not spread, surgical removal is the primary goal and offers the only chance for a cure [9]. However, because many VIPomas are diagnosed after they have spread to the liver, doctors frequently use a “toolbox” of other therapies [7]. These may include targeted radiation therapies like PRRT, which seek out the tumor cells, or oral medications that slow tumor growth [10][11]. The choice of treatment is highly individualized, based on the tumor’s grade and how much hormone it is producing [12].

While most cases are “sporadic” and occur as a single tumor, about 5% of VIPomas are part of a hereditary condition called Multiple Endocrine Neoplasia type 1 (MEN1) [1]. Patients with this subtype may develop other endocrine issues, such as parathyroid or pituitary tumors, and should seek genetic counseling for their family members [13][14]. Regardless of the subtype, long-term monitoring is essential [15]. Because these tumors can return many years after successful treatment, lifelong surveillance through regular clinical review, blood tests and imaging helps ensure that any changes are caught and managed early [16][17].

In this guide

6 chapters

01

Understanding VIPoma and Urgent Warning Signs

Learn how VIPoma causes WDHA syndrome, watery diarrhea, dehydration, and low potassium, plus emergency warning signs and treatment with fluids and octreotide.

02

The Biology of VIPoma and Why It Is Misdiagnosed

Learn how pancreatic VIPoma causes secretory diarrhea, why it is mistaken for IBS and other conditions, and how VIP testing and MEN1 evaluation help diagnosis.

03

Labs, Scans, and Your Pathology Report

Learn how VIPoma is diagnosed, including accurate VIP blood testing, stool osmotic gap, CT/MRI, DOTATATE PET/CT, Ki-67, grading, and pathology report terms.

04

Acute Management and Stabilizing the Crisis

Learn how a VIPoma crisis is stabilized with IV fluids, electrolytes, and octreotide, why surgery is delayed, and how doctors decide when treatment is safe.

05

Standard Treatments for the Tumor

Learn how VIPoma treatment varies by tumor spread, including surgery, liver-directed therapy, PRRT, somatostatin analogs, targeted drugs, and chemotherapy.

06

Life After Treatment: Monitoring and Long-Term Care

Learn how VIPoma follow-up detects late recurrence, including VIP blood tests, potassium checks, CT or MRI scans, MEN1 surveillance, and emotional support.

Common questions in this guide

What is a VIPoma, and what does WDHA syndrome mean?
A VIPoma is a rare neuroendocrine tumor that makes excessive vasoactive intestinal peptide, or VIP, most often in the pancreas. The excess hormone can cause WDHA syndrome, named for watery diarrhea, low potassium, and low stomach acid.
Can VIPoma cause dangerously low potassium and dehydration?
Yes. VIPoma-related diarrhea can continue even when you are not eating and may cause severe dehydration, kidney injury, and dangerously low potassium. Severe diarrhea, marked weakness, or extreme fatigue needs prompt medical evaluation.
How is VIPoma stabilized at the beginning of treatment?
Initial care focuses on replacing lost fluids and electrolytes, especially potassium, while clinicians assess the tumor. Somatostatin analogs such as octreotide may reduce VIP release and diarrhea, helping stabilize the body.
Can surgery cure a VIPoma?
Surgery is the main treatment when the VIPoma is localized and has not spread, and complete removal may offer the only chance for cure. If the tumor has spread, especially to the liver, treatment usually combines hormone control with tumor-directed therapies chosen according to grade, spread, and hormone production.
What treatments are available if a VIPoma has spread?
For VIPoma that has spread, doctors may use somatostatin analogs to control hormone-related symptoms, peptide receptor radionuclide therapy (PRRT) to target tumor cells, and oral medicines that slow tumor growth. The treatment plan depends on tumor grade, location and burden, and how much VIP it produces.
Should someone with VIPoma be evaluated for MEN1?
About 5% of VIPomas are associated with MEN1, an inherited condition that can also cause parathyroid or pituitary tumors. A personal or family history of MEN1 or related endocrine tumors may lead a clinician to recommend genetic counseling and testing.
Why is lifelong follow-up important after VIPoma treatment?
VIPoma can return years after treatment, so long-term or lifelong follow-up is important. Monitoring may include clinical visits, blood tests, and imaging to detect recurrent or changing disease early.

Get notified when new evidence is published on pancreatic vasoactive intestinal peptide producing tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Vasoactive intestinal peptide secreting tumour: An overview.

    Una Cidon E

    World journal of gastrointestinal oncology 2022; (14(4)):808-819 doi:10.4251/wjgo.v14.i4.808.

    PMID: 35582098
  2. 2

    All you need to know about VIPoma: Review on the latest studies.

    Karele EN

    Presse medicale (Paris, France : 1983) 2024; (53(2)):104222 doi:10.1016/j.lpm.2023.104222.

    PMID: 38109967
  3. 3

    Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system.

    Iwasaki M, Akiba Y, Kaunitz JD

    F1000Research 2019; (8()) doi:10.12688/f1000research.18039.1.

    PMID: 31559013
  4. 4

    Metastatic mixed VIPoma/PPoma-induced diarrhoea causing renal failure.

    Brown G, Monaghan AM, Fristedt R, et al.

    Endocrinology, diabetes & metabolism case reports 2022; (2022()).

    PMID: 36001009
  5. 5

    Pancreatic VIPomas from China: Case reports and literature review.

    Chen C, Zheng Z, Li B, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2019; (19(1)):44-49 doi:10.1016/j.pan.2018.10.007.

    PMID: 30391116
  6. 6

    Case Report: Irreversible Watery Diarrhea, Severe Metabolic Acidosis, Hypokalemia and Achloridria Syndrome Related to Vasoactive Intestinal Peptide Secreting Malignant Pheochromocytoma.

    Negro A, Verzicco I, Tedeschi S, et al.

    Frontiers in endocrinology 2021; (12()):652045 doi:10.3389/fendo.2021.652045.

    PMID: 33815297
  7. 7

    Efficacy of treatments for VIPoma: A GTE multicentric series.

    Brugel M, Walter T, Goichot B, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(8)):1531-1539 doi:10.1016/j.pan.2021.08.001.

    PMID: 34404601
  8. 8

    Treatment options of metastatic and nonmetastatic VIPoma: a review.

    Azizian A, König A, Ghadimi M

    Langenbeck's archives of surgery 2022; (407(7)):2629-2636 doi:10.1007/s00423-022-02620-7.

    PMID: 35931878
  9. 9

    Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

    Bartsch DK, Mais L, de Mestier L, et al.

    Journal of neuroendocrinology 2026; (38(7)):e70219 doi:10.1111/jne.70219.

    PMID: 42338092
  10. 10

    Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

    Zandee WT, Brabander T, Blažević A, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(4)):1336-1344 doi:10.1210/jc.2018-01991.

    PMID: 30566620
  11. 11

    Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients.

    Hayes AR, Mak IYF, Evans N, et al.

    Neuroendocrinology 2021; (111(9)):863-875 doi:10.1159/000511662.

    PMID: 32950978
  12. 12

    European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.

    Hofland J, Falconi M, Christ E, et al.

    Journal of neuroendocrinology 2023; (35(8)):e13318 doi:10.1111/jne.13318.

    PMID: 37578384
  13. 13

    VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation.

    Fujiya A, Kato M, Shibata T, Sobajima H

    BMJ case reports 2015; (2015()).

    PMID: 26564120
  14. 14

    Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group.

    van Leeuwaarde RS, van Nesselrooij BP, Hermus AR, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(3)):1159-65 doi:10.1210/jc.2015-3766.

    PMID: 26751192
  15. 15

    Prevalence of Diagnostic Methods and Treatment Modalities in Vipoma Patients: A Rare Cause of Hormone-Mediated Diarrhea.

    Amiri FS

    Indian journal of endocrinology and metabolism 2019; (23(3)):318-325 doi:10.4103/ijem.IJEM_105_19.

    PMID: 31641634
  16. 16

    A case of vasoactive intestinal peptide-secreting tumor (VIPoma) arising from MEN1 inactivation which recurred 15 years after the initial resection.

    Sakurai M, Wakabayashi T, Kondo Y, et al.

    Endocrine journal 2023; (70(6)):573-579 doi:10.1507/endocrj.EJ22-0578.

    PMID: 36889692
  17. 17

    Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.

    Schizas D, Mastoraki A, Bagias G, et al.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2019; (24(2)):415-423.

    PMID: 31127985

This page is for informational purposes only and does not constitute medical advice. Severe diarrhea, dehydration, or possible low potassium need prompt medical attention; your care team should guide VIPoma testing and treatment.